Abstract:AIM:To investigate the role of bone marrow-derived endothelial progenitor cells（EPCs） in the angiogenesis of hepatocellular carcinoma（HCC）.METHODS:The bone marrow of HCC mice was reconstructed by transplanting green fluorescent protein（GFP） + bone marrow cells.The concentration of circulating EPCs was determined by colony-forming assays and fluorescence-activated cell sorting.Serum and tissue levels of vascular endothelial growth factor（VEGF） and colony-stimulating factor（CSF） were quantified by enzyme-linked immunosorbent assay.The distribution of EPCs in tumor and tumor-free tissues was detected by immunohistochemistry and real-time polymerase chain reaction.The incorporation of EPCs into hepatic vessels was examined by immunofluorescence and immunohistochemistry.The proportion of EPCs in vessels was then calculated.RESULTS:The HCC model was successful established.The flow cytometry analysis showed the mean percentage of CD133CD34 and CD133VEGFR2 double positive cells in HCC mice was 0.45% ± 0.16% and 0.20% ± 0.09% respectively.These values are much higher than in the sham-operation group（0.11% ± 0.13%,0.05% ± 0.11%,n = 9） at 14 d after modeling.At 21 d,the mean percentage of circulating CD133CD34 and CD133VEGFR2 cells is 0.23% ± 0.19%,0.25% ± 0.15% in HCC model vs 0.05% ± 0.04%,0.12% ± 0.11% in control.Compared to the transient increase observed in controls,the higher level of circulating EPCs were induced by HCC.In addition,the level of serum VEGF and CSF increased gradually in HCC,reaching its peak 14 d after modeling,then slowly decreased.Consecutive sections stained for the CD133 and CD34 antigens showed that the CD133+ and CD34+ VEGFR2 cells were mostly recruited to HCC tissue and concentrated in tumor microvessels.Under fluorescence microscopy,the bone-marrow（BM）-derived cells labeled with GFP were concentrated in the same area.The relative levels of CD133 and CD34 gene expression were elevated in tumors,around 5.0 and 3.8 times that of the tumor free area.In frozen liver sections from HCC mice,cells co-expressing CD133 and VEGFR2 were identified by immunohistochemical staining using anti-CD133 and VEGFR2 antibodies.In tumor tissue,the double-positive cells were incorporated into vessel walls.In immunofluorescent staining.These CD31 and GFP double positive cells are direct evidence that tumor vascular endothelial cells（VECs） come partly from BM-derived EPCs.The proportion of GFP CD31 double positive VECs（out of all VECs） on day 21 was around 35.3% ± 21.2%.This is much higher than the value recorded on day 7 group（17.1% ± 8.9%）.The expression of intercellular adhesion molecule 1,vascular adhesion molecule 1,and VEGF was higher in tumor areas than in tumor-free tissues.CONCLUSION:Mobilized EPCs were found to participate in tumor vasculogenesis of HCC.Inhibiting EPC mobilization or recruitment to tumor tissue may be an efficient strategy for treating HCC.

Endothelial cell colony forming units derived from malignant breast diseases are resistant to tumor necrosis factor-α-induced apoptosis

Endothelial Cells Activate the Cancer Stem Cell-Associated Nanogp8 Pathway in Colorectal Cancer Cells in A Paracrine Fashion

Abstract 1281: Endothelial Cells Promote the Cancer Stem Cell Phenotype of Human Colorectal Cancer Cells

Identification and Clinical Significance of Mobilized Endothelial Progenitor Cells in Tumor Vasculogenesis of Hepatocellular Carcinoma

High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy.

Circulating endothelial progenitor cell: a promising biomarker in clinical oncology

Endothelial Progenitors Promote Hepatocarcinoma Intrahepatic Metastasis Through Monocyte Chemotactic Protein-1 Induction of Microrna-21

Human Hepatocellular Carcinoma Tumor-Derived Endothelial Cells Manifest Increased Angiogenesis Capability and Drug Resistance Compared with Normal Endothelial Cells

Antitumor effects of CD40 ligand-expressing endothelial progenitor cells derived from human induced pluripotent stem cells in a metastatic breast cancer model.

Circulating Tumor-Derived Endothelial Cells: an Effective Biomarker for Breast Cancer Screening and Prognosis Prediction

Tumor necrosis factor receptor 2 promotes endothelial cell-mediated suppression of CD8+ T cells through tuning glycolysis in chemoresistance of breast cancer

Significance and Therapeutic Implications of Endothelial Progenitor Cells in Angiogenic-Mediated Tumour Metastasis

Endothelial Precursor Cells Promote Angiogenesis in Hepatocellular Carcinoma

Vascular Endothelial Cells Facilitated HCC Invasion and Metastasis Through the Akt and NF-κB Pathways Induced by Paracrine Cytokines

Predictive and Prognostic Significance of Circulating Endothelial Cells in Advanced Non-Small Cell Lung Cancer Patients

Tumour endothelial cells for translational research and therapeutics

A Preliminary Analysis of Circulating Tumor Microemboli from Breast Cancer Patients during Follow-Up Visits

The Role of Endothelial Progenitor Cells in Tumour Vasculogenesis

TFEB and TFE3 Depletion Increases Cancer Stem Cell Characteristics and EMT in Triple‐Negative Breast Cancer

Identification and Significance of Mobilized Endothelial Progenitor Cells in Tumor Neovascularization of Renal Cell Carcinoma.

Paracrine signalling in breast cancer: Insights into the tumour endothelial phenotype